We live in the era of the Internet of things, and Artificial intelligence (AI) continues to define this century. The adoption of IoT and AI technologies is still in its early stages in the healthcare industry. However, it is clear that these technologies have the potential to revolutionize the healthcare industry. Artificial intelligence is a broad term that can include natural language processing, physical robots, machine learning, robotic automation, and rule-based expert systems. The rise of computerized systems and medical devices in efficiently and safely diagnosing, coordinating care, and treating clearly indicates that AI has all the potential that primary care providers need. Telehealth, a product of AI, has proven to be an effective tool in remotely monitoring, diagnosing, and triaging patients for COVID-19. It facilitated the patients to utilize the healthcare services from the doorstep. According to Goldman Sachs, Telehealth and other related digital health technology can save approximately $300 billion in costs related to managing certain chronic conditions.
With the same vision, Jasjit S. Suri is focused on implementing the rules and techniques of Artificial Intelligence in Biomedicine and Healthcare. He started his career in 1990 in the fields of computer sciences, industrial computer engineering, software and hardware engineering, and biomedical engineering. He is an American industrialist, innovator, and chief technology officer.
Jasjit S. Suri currently sits as the Chairman of Roseville, USA, AtheroPoint, CA, where he has worked with great dedication and came up with imaging technologies for the diagnosis of stroke and cardiovascular disease. Being very enthusiastic about imparting knowledge of medical devices in the health industry, he has also been a fellow member of prestigious societies like AIMBE, APVS, AIUM, IEEE, and SVM. He has successfully made 50 US and European patents and led teams for 510(K) regulatory clearance of medical device products in healthcare.
The design of his innovations typically includes AI-based multithreaded dual architectures for collaborative platforms such as desktops and mobile devices simultaneously. Suri, in his career, has mainly focused on product development and has been active as a chief technology officer since 2004 for future product designs and building intellectual property portfolios.
One of his most prominent achievements includes Artemis development. It is an image-guided surgical robotic device for three-dimensional sonography with needle tracking, assisting in the diagnosis and treatment of prostate cancer. It further assists in the design and development of a system for prostate biopsy. The rest of the achievements include AtheroEdge 3.0 for Ultrasound and AI-based cardiovascular risk assessment and coronary artery disease risk prediction, Atheromatic 2.0 for AI-based system for symptomatic vs. asymptomatic plaque tissue characterization, AtheroCloud for cloud-based Cardiovascular Disease (CVD) risk assessment, and plaque vulnerability, an image-guided surgery system for neurological procedures applications, Voyager, DSAex 2000 – Digital Subtraction Angiography system, Breast uptake analysis system, for breast lesion detection using MRI, and more recently, COVLIAS 1.0 for diagnosis of COVID-19 using CT.
Quite recently, little attention has been paid to characterizing atherosclerotic plaque tissue in Rheumatoid Arthritis (RA) or predicting CVD risk using automated intelligence-based techniques. However, Dr. Suri firmly believes that automated intelligence-based techniques have clinical applications as part of early RA screening tools to identify patients at risk for CVD.
Suri sticks to bringing a revolution in Artificial Intelligence because he believes that AI technologies can help healthcare organizations make the most of their data, resources, and assets. It can increase efficiency and improve the performance of clinical and operational workflows, financial operations, and processes. One of the most effective services that Artificial Intelligence can offer is to connect disparate data so that a more unified picture of individuals behind the data can be made.
For all the innovative services that Suri has provided in the healthcare world, he has been rewarded with Life Time Achievement Award from Marquis in 2018 and Director General’s Gold Medal in 1980.
